• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Allergy Clin Immunol . Severe SARS-CoV-2 Disease In The Context Of A NFκB2 Loss-Of-Function Pathogenic Variant

tetano

Editor, Senior Moderator
J Allergy Clin Immunol


. 2020 Sep 29;S0091-6749(20)31331-2.
doi: 10.1016/j.jaci.2020.09.020. Online ahead of print.
Severe SARS-CoV-2 Disease In The Context Of A NFκB2 Loss-Of-Function Pathogenic Variant


Roshini S Abraham[SUP] 1 [/SUP], Joanna M Marshall[SUP] 2 [/SUP], Hye Sun Kuehn[SUP] 3 [/SUP], Cesar M Rueda[SUP] 2 [/SUP], Amber Gibbs[SUP] 2 [/SUP], Will Guider[SUP] 4 [/SUP], Claire Stewart[SUP] 4 [/SUP], Sergio D Rosenzweig[SUP] 3 [/SUP], Huanyu Wang[SUP] 2 [/SUP], Sophonie Jean[SUP] 2 [/SUP], Mark Peeples[SUP] 5 [/SUP], Tiffany King[SUP] 5 [/SUP], W Garrett Hunt[SUP] 6 [/SUP], Jonathan R Honegger[SUP] 7 [/SUP], Octavio Ramilo[SUP] 7 [/SUP], Peter J Mustillo[SUP] 8 [/SUP], Asuncion Mejias[SUP] 7 [/SUP], Monica I Ardura[SUP] 6 [/SUP], Masako Shimamura[SUP] 7 [/SUP]



Affiliations

Abstract

Background: SARS-CoV-2 is a novel coronavirus that emerged recently and has created a global pandemic. Symptomatic SARS-CoV-2 infection, termed Coronavirus disease 2019 (COVID-19), has been associated with a host of symptoms affecting numerous organ systems, including lungs, cardiovascular system, kidney, central nervous system, gastrointestinal tract and skin among others.
Objective: While several risk factors have been identified related to complications from and severity of COVID-19, much about the virus remains unknown. The host immune response appears to affect the outcome of disease. It is not surprising that patients with intrinsic or secondary immune compromise might be particularly susceptible to complications from SARS-CoV-2 infection. Pathogenic loss-of-function (LOF) or gain-of-function (GOF) heterozygous variants in NFκB2 have been reported to be associated with either a combined immunodeficiency (CID) or common variable immunodeficiency (CVID) phenotype.
Methods: We evaluated the functional consequence and immunological phenotype of a novel NFKB2 LOF variant in a 17y old male patient and describe the clinical management of SARS-CoV-2 infection in this context.
Results: This patient required a 2-week hospitalization for SARS-CoV-2 infection, including seven days of mechanical ventilation. We used biological therapies to avert potentially fatal acute respiratory distress syndrome and treat hyperinflammatory responses. The patient had an immunological phenotype of B cell dysregulation with decreased switched memory B cells. Despite the underlying immune dysfunction, he recovered from the infection with intense management.
Conclusions: This clinical case exemplifies some of the practical challenges in management of patients with SARS-CoV-2 infection, especially in the context of underlying immune dysregulation.

Keywords: COVID-19; NFkappaB; NFκB pathway; NFκB2; SARS-CoV-2; immunodeficiency.
 
Back
Top Bottom